Thymulin Dosage Reported in Research Studies

In plain English

There is no established human dose of thymulin. It is a research peptide, not an approved medicine, so this page does not tell anyone what to take — it records what scientists gave to animals and cells, and by what route. The numbers below are small (nanograms to a few micrograms per animal) and they belong to specific experiments in mice, chickens, and rats. Read them as a catalogue of the literature, not as guidance. Thymulin dosage in research is reported per study; standardized human dosing does not exist in the public record.

Thymulin dosage reported in research studies

Reported thymulin doses sit in the nanogram-to-low-microgram range per animal, varying by model and route. Representative figures from the cited record:

• Mouse, LPS pancreatic-protection model: 50 µg per animal, intraperitoneal, before the LPS challenge ^[13].
• Mouse, virus-induced diabetes/myocarditis model: 10-50 µg per animal, subcutaneous, before challenge ^[14].
• Chicken, antiviral NK-cell model: 10 ng and 50 ng per 100 g body weight, in vivo ^[15].
• Mouse, systemic-inflammation model: thymulin given daily for two weeks before LPS; the abstract reports the schedule rather than a numeric dose ^[6].
• Rodent CNS / anti-inflammatory work: nanogram-to-low-microgram amounts, including intracerebroventricular doses, per the review record ^[4].

Gene-therapy studies do not report a peptide dose at all — they deliver a single vector dose (adenoviral or nanoparticle-borne plasmid) engineered to produce thymulin over time, a strategy adopted specifically because the native peptide is short-lived ^[5][7]. None of these is a human dose, and none should be read as one.

How thymulin is administered in research

The routes studied span parenteral, central, pulmonary, and in-vitro delivery. Across the cited work these include intraperitoneal ^[13], subcutaneous ^[14], intracerebroventricular ^[4], intratracheal (for inhaled gene therapy) ^[7], intramuscular and intracerebral (for gene-therapy vectors) ^[5], topical (the zinc-thymulin alopecia pilot), and direct in-vitro incubation with cultured cells ^[8]. Human work is the sparse exception: early controlled and open trials used a synthetic analog (nonathymulin) and FTS-Zn, and a small open-label pilot studied a topical zinc-thymulin preparation. There is no approved human injectable thymulin product.

What is the half-life of thymulin?

What is the half-life of thymulin?

Native thymulin is a small peptide with a short circulating half-life, and its precise human pharmacokinetic half-life is not well characterized in the public literature. The clearest evidence for the short-life problem is indirect but telling: the gene-therapy approaches were developed expressly to sustain circulating thymulin levels over time, which would be unnecessary if the native peptide persisted ^[5]. Treat any specific half-life figure with caution — the public record does not establish one for humans.

Stability and the zinc requirement

One stability fact dominates all dose considerations: activity requires the bound zinc ion. Zinc chelation — by EDTA or Chelex, for instance — abolishes activity, and the apopeptide remains inactive until zinc is restored ^[1][2]. Any reported thymulin effect is therefore an effect of the zinc-bound complex, and the zinc status of a system materially shapes the result. This is why the literature so often pairs thymulin findings with zinc measurements, and why thymulin-specific dose-response is hard to read cleanly apart from zinc.

What is the dosage of thymulin peptide?

What is the dosage of thymulin peptide?

There is no established human dosage of thymulin peptide. It is a research peptide handled for laboratory use, and reported doses are study findings in animal models — nanogram-to-microgram ranges by route and species, as catalogued above — not protocols for people. Anyone encountering a specific human dosing schedule for thymulin should treat it as unsupported by the published record.